Methocarbamol
FDA Label NDC 61919-627
Full FDA labeling including Indications, Dosage, Usage, and Precautions
Structured Product Label
The following Structured Product Label (SPL) was submitted to the FDA by Directrx for the product Methocarbamol (NDC 61919-627). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.
This specific version of the label includes detailed information regarding description, clinical pharmacology, pharmacokinetics, elderly, special populations, indications and usage, contraindications, warnings, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.
Label Section Quick Index
Clinical Pharmacology
Pharmacokinetics
Elderly
Special Populations
The clearance of methocarbamol in 8 renally-impaired patients on maintenance hemodialysis was reduced about 40% compared to 17 normal subjects, although the mean (± SD) elimination half-life in these two groups was similar: 1.2 (± 0.6) versus 1.1 (± 0.3) hours, respectively.
Indications And Usage
Contraindications
Warnings
Precautions
Overdosage
Dosage And Administration
How Supplied
Other
Package Label
Label (Methocarb627)
* Please review the disclaimer below.
